E0
E08A.F Exagen Inc
- Market cap
- EUR 123M
- P/E
- -
- P/B
- 12.84x
- ROE
- -117.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is E08A.F undervalued?
Graham numberThe Graham number of Exagen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Exagen Inc fundamental analysis
No fundamental analysis for Exagen Inc yet.
Exagen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presen…
Full company profileExagen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Exagen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 26.8M | 32.4M | 40.4M | 42.0M | 48.3M | 45.6M | 52.5M | 55.6M | 66.6M | 74.5M |
| Gross Profit | - | 12.7M | 17.1M | 21.6M | 25.4M | 27.7M | 21.3M | 29.5M | 33.1M | 38.8M | 44.8M |
| Operating Income | - | -7.89M | -4.88M | -9.30M | -15.2M | -24.1M | -40.5M | -22.8M | -13.6M | -14.1M | -10.3M |
| EBITDA | - | -22.6M | -4.36M | -7.93M | -13.7M | -24.1M | -45.2M | -19.2M | -11.1M | -13.5M | -6.86M |
| Net Income | - | -25.6M | -8.01M | -12.0M | -16.7M | -26.9M | -47.4M | -23.7M | -15.1M | -20.0M | -14.3M |
| EPS | - | -2.28 | -0.71 | -0.96 | -1.32 | -1.66 | -2.86 | -1.39 | -0.86 | -0.87 | -0.59 |
| Balance Sheet | |||||||||||
| Total Assets | - | 20.4M | 28.9M | 88.3M | 78.4M | 123M | 86.2M | 56.9M | 44.7M | 58.0M | 51.9M |
| Total Liabilities | - | 25.0M | 35.6M | 32.7M | 36.5M | 38.5M | 43.8M | 34.3M | 35.1M | 40.6M | 39.7M |
| Shareholders' Equity | - | -4.64M | -6.73M | 55.7M | 41.8M | 84.9M | 42.5M | 22.7M | 9.54M | 17.4M | 12.2M |
| Cash & Short-term Investments | - | 11.2M | 13.2M | 72.1M | 57.4M | 99.4M | 62.4M | 36.5M | 22.0M | 32.2M | 24.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.9M | -11.0M | -9.30M | -9.71M | -14.1M | -20.3M | -32.1M | -14.5M | -13.3M | -13.6M | -12.9M |
| Capital Expenditure | 0.00 | 567K | 199K | 403K | 455K | 2.37M | 4.32M | 828K | 515K | 641K | 1.54M |
| Free Cash Flow | - | -11.5M | -9.50M | -10.1M | -14.5M | -22.6M | -36.5M | -15.3M | -13.8M | -14.3M | -14.4M |
| Ratios | |||||||||||
| ROE | - | - | - | -21.6% | -39.9% | -31.6% | -111.6% | -104.4% | -158.4% | -114.3% | -117.3% |
| ROA | - | -125.7% | -27.7% | -13.6% | -21.3% | -21.8% | -55.0% | -41.6% | -33.8% | -34.4% | -27.6% |
| Net Profit Margin | - | -95.6% | -24.7% | -29.8% | -39.8% | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% | -19.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Exagen Inc dividends
Exagen Inc has not paid dividends in the last 9 fiscal years.
Who owns Exagen Inc
- Insiders 24.25%
- Institutions 44.83%
- Public & others 30.93%
- Shares outstanding 25.4M
- Free float 13.5M
Exagen Inc company profile
- Company name
- Exagen Inc
- Ticker
- E08A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 216
- Fiscal year end
- December
- Address
- 1261 Liberty Way, Vista, CA, United States, 92081
- Phone
- 760 560 1501
- Website
- exagen.com
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Exagen Inc management
6- Dr. Tina S. Nova Ph.D.Executive Chairman of the Board of Directors · born 1954
- Mr. John AballiCEO, President & Director · born 1985
- Mr. Jeffrey G. BlackCFO & Corporate Secretary · born 1969
- Dr. Michael MahlerChief Scientific Officer
- Ms. Tina Jacobsen CFAVice President of Investor Relations
- Dr. Prashanti Reddy M.D.Chief Medical Officer